327 reports of this reaction
2.3% of all DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE reports
#8 most reported adverse reaction
VISION BLURRED is the #8 most commonly reported adverse reaction for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, manufactured by Thea Pharma Inc.. There are 327 FDA adverse event reports linking DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE to VISION BLURRED. This represents approximately 2.3% of all 14,333 adverse event reports for this drug.
Patients taking DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE who experience vision blurred should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VISION BLURRED is a less commonly reported adverse event for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, but still significant enough to appear in the safety profile.
In addition to vision blurred, the following adverse reactions have been reported for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE:
The following drugs have also been linked to vision blurred in FDA adverse event reports:
VISION BLURRED has been reported as an adverse event in 327 FDA reports for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
VISION BLURRED accounts for approximately 2.3% of all adverse event reports for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, making it a notable side effect.
If you experience vision blurred while taking DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.